Evaluating the state of the global and domestic pharmaceutical market, Dmytro Shymkiv, the head of the Board of Directors of the Darnytsa Group, encouraged the audience with good news. Due to his report, the Darnytsa company managed to launch new products — 10 new brands during the last year. At the same time, one of these drugs completes the line of two- and three-component medicines used in treating arterial hypertension.
In addition, Dmytro Shymkiv informed that the Covid-19 pandemic restrictions have led to a deterioration in the situation in the global medicines market. So, taking an example of India — the largest supplier of pharmaceutical raw materials and finished drugs — it has limited exports and ultimately closed its borders in the struggle against coronavirus. Many European countries were obliged to take such actions that led them to the verge of collapse because of the lack of medicines and other pharmaceutical products.
However, such a deteriorating situation played into the Ukrainian manufacturers’ hands and allowed them to speed up and increase the export of medicines to the EU. Moreover, Ukraine managed to avoid drug shortages. And such advantages are due to a well-developed pharmaceutical industry.
Domestic manufacturers of medications and pharmaceutical products could quickly refocus themselves and account for the growing demand of Ukrainians for medicines. And among those manufacturers is the Darnytsia closed joint-stock company which take the leading position.
Dmytro Shymkiv clarified that entering the European market during a pandemic is a situational profit. But thanks to such a move, new opportunities have opened up for the Ukrainian pharma. However, in order to implement those opportunities in full, it is necessary to amend the Deep and Comprehensive Free Trade Area (DCFTA) Agreement between Ukraine and the EU.
Following this goal, representatives of domestic pharmaceutical companies led by the Darnytsia Group put forward an initiative to promote the process of mutual recognition of GMP certificates. Dmytro Shymkiv believes that this issue will be resolved very soon since Ukrainian products are not inferior to their European counterparts regarding quality, efficiency, and safety.
When it comes to the perspective export of Ukrainian medicines in the eastern direction, the top manager of Darnytsia reported that Ukraine has high chances in this case. Despite the increased competition with Indian and Chinese drugs, the new brands launched last year by the Darnytsia factory are absolutely capable of appealing to millions of Asian doctors and patients.